Abstract:Objective The microbiota–gut–brain axis, especially the inflammatory pathway, may play a critical role in the pathogenesis of cognitive impairment in major depressive disorder (MDD). However, studies on the microbiota-inflammatory-cognitive function axis in MDD are lacking. The aim of the present study was to analyze the gut microbiota composition and explore the correlation between gut microbiota and inflammatory factors, cognitive function in MDD patients. Method Study participants included 66 first-episode, drug naïve MDD patients as well as 43 healthy subjects (HCs). The composition of fecal microbiota was evaluated using16S rRNA sequencing and bioinformatics analysis. The cytokines such as hs-CRP, IL-1β, IL-6, IL-10, and TNF-α in peripheral blood were detected via enzyme linked immunosorbent assay (ELISA); assessment of cognitive functions was performed using the Color Trail Test (CTT), The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Stroop Color-Word Test (SCWT). Results We found that compared with HCs, MDD patients had cognitive impairments and showed different α-diversity and β-diversity of gut microbiota composition. LDA effect size (LEfSe) analysis found MDD have higher Deinococcaceae and lower Bacteroidaceae, Turicibacteraceae, Clostridiaceae and Barnesiellaceae at family level. Deinococcus and Odoribacter was higher in the MDD group, however, Bacteroides, Alistipes, Turicibacter, Clostridium, Roseburia , and Enterobacter were lower at genus level. Furthermore, In MDD patients, the Bacteroidaceae and Bacteroides were both positively correlated with hsCRP, CCT1, CCT2. Alistipes was positively correlated with IL-6, Word time, Color time, Word-Color time, Color-Word time and negatively correlated with Delayed Memory, Total score and Standardized score. Turicibacteraceae and Turicibacter were both negatively correlated with IL-1β and IL-6. Conclusion The present findings confirm that the gut microbiota in MDD patients have altered gut microbes that are closely associated with inflammatory factors and cognitive function in MDD patients.

Cytokine profile in first-episode drug-naïve major depressive disorder patients with or without anxiety

Changes in the Serum Levels of Inflammatory Cytokines in Antidepressant Drug-Naïve Patients with Major Depression

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder

The Prevalence and Clinical Correlates of Anxiety in Chinese Patients with First-Episode and Drug-Naïve Major Depressive Disorder at Different Ages of Onset

Inflammatory cytokines, complement factor H and anhedonia in drug-naïve major depressive disorder

Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression.

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

Features of gut microbiota and short-chain fatty acids in patients with first-episode depression and their relationship with the clinical symptoms

Interleukin-6 is correlated with amygdala volume and depression severity in adolescents and young adults with first-episode major depressive disorder

Sex differences in the association of plasma cytokines and neurocognition in first-episode major depressive disorder

Ghrelin and depressive symptoms in patients with first‐episode drug‐naïve major depressive disorder: The mediating role of hypothalamic‐pituitary‐adrenal axis

Prevalence and related factors of anxiety in first episode and drug naïve Chinese Han outpatients with psychotic major depression

Prevalence and clinical profile of comorbid anxiety in young adult patients with first-episode and drug-naive major depressive disorder

An Analysis of Plasma Reveals Proteins in the Acute Phase Response Pathway to Be Candidate Diagnostic Biomarkers for Depression

Combined Serum IL-6, C-reactive Protein, and Cortisol May Distinguish Patients with Anhedonia in Major Depressive Disorder.

Gut Microbiome Composition Linked to Inflammatory Factors and Cognitive Functions in First-Episode, Drug-Naive Major Depressive Disorder Patients

Abnormal erythrocyte fatty acid composition in first-diagnosed, drug-naïve patients with depression

Comparisons of Serum Interleukin-8 Levels in Major Depressive Patients With Drug-Free Versus SSRIs Versus Healthy Controls

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications

Differences in cytokines between patients with generalised anxiety disorder and panic disorder

Prevalence and clinical correlates of abnormal lipid metabolism in older Chinese patients with first-episode drug-naïve major depressive disorder